{
    "clinical_study": {
        "@rank": "11726", 
        "acronym": "PrOteCT", 
        "arm_group": [
            {
                "arm_group_label": "Pro-Omega LDL", 
                "arm_group_type": "Experimental", 
                "description": "3 capsules 1000 mg BID for 8 weeks"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "3 capsules BID for 8 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "Pro-Omega LDL reduces low-density lipoprotein cholesterol and triglycerides in subjects with\n      mixed hyperlipoproteinemia."
        }, 
        "brief_title": "Efficacy Study of Daily Pro-Omega LDL for Low-Density Lipoprotein Cholesterol and Triglyceride Reduction", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Mixed Hyperlipoproteinemia", 
        "condition_browse": {
            "mesh_term": [
                "Hyperlipidemia, Familial Combined", 
                "Hyperlipoproteinemias"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men or women, \u226518 years of age.\n\n          -  History (>3months) of LDL-C \u2265130 mg/dl to \u2264190 mg/dL\n\n          -  Triglycerides (TG) > 200 to <750 mg/dL\n\n          -  Able to understand and cooperate with study procedures, and have signed a written\n             informed consent prior to any study procedures.\n\n          -  Willing to maintain a stable diet and level of activity throughout the trial.\n             Willing to maintain current activity level and diet throughout the trial.\n\n          -  If, of childbearing age, must be on a medically approved form of birth control as\n             identified by the investigator in this trial\n\n          -  History (> 3 months) of taking  a statin medication  (HMG-CoA reductase inhibitor,\n             including Lipitor, Zocor, Crestor, Pravachol, Lescol, Livalo) without problems, and\n             would be willing to withdraw from statin for the duration of the trial (4 weeks\n             without statin prior to randomization for washout period, then treatment with\n             protocol medication for 10 week duration of the trial)\n\n        Exclusion Criteria:\n\n          -  Individuals with intolerance of, or allergy to red yeast rice or omega 3 fatty acids.\n\n          -  Individuals currently taking a statin (HMG-CoA Reductase inhibitor) including\n             Lipitor, Zocor, Crestor, Pravachol, Lescol, Livalo) or other lipid metabolism\n             altering product within four (4) weeks prior to randomization who do not wish to\n             withdraw from therapy.\n\n          -  Individual taking prescription or over the counter medications (including dietary\n             supplements) known to alter lipid metabolism within four (4) weeks of randomization.\n             Medications excluded within 4 weeks of randomization are: prescription omega-3 fatty\n             acids, statins, bile acid sequestrants, cholesterol absorption inhibitors, niacin or\n             fibrates.  Dietary supplements excluded within 4 weeks prior to randomization are:\n             L-carnitine, policosanol, guggulipid, sterol/stanol products, red rice yeast\n             supplements, garlic supplements, soy isoflavone supplements, niacin or its analogues,\n             probiotics and dietary fiber supplements (including >2 teaspoons Metamucil or\n             psyllium-containing supplements per day and prebiotics), or any dietary supplement or\n             vitamin complex product containing omega 3 acids or fish oil.\n\n          -  Use of systemic corticosteroids, androgens (except androgens for hypogonadism to\n             restore normal levels), phenytoin, erythromycin and other macrolides, and thyroid\n             hormones (except stable-dose thyroid replacement therapy for four (4) weeks prior to\n             enrollment).\n\n          -  Use of the anticoagulants warfarin (Coumadin) or dabigatran (Pradaxa), apixaban\n             (Eliquis) or rivaroxaban (Xarelto).\n\n          -  Pregnant or lactating women, or women of childbearing potential who are not complying\n             with an approved method of contraception.  A woman is considered to be of\n             childbearing potential unless she is post-hysterectomy, one or more years\n             postmenopausal, or one or more years post-tubal ligation.\n\n          -  Individuals with a history of myopathy, defined as a creatine phosphokinase (CPK)\n             >450 U/L and/or unexplained muscle pain on statins.\n\n          -  Type I or type II diabetes mellitus or HbA1c \u22657.0%\n\n          -  History of significant cardiovascular or coronary heart disease (CVD or CHD) as\n             defined by having had a coronary artery bypass procedure, coronary stent or\n             angioplasty, or myocardial infarction.\n\n          -  Current or recent (within six months) history of significant gastrointestinal, renal,\n             pulmonary, hepatic or biliary disease\n\n          -  History of cancer, other than non-melanoma skin cancer and basal cell carcinoma,\n             within the previous five years.\n\n          -  Poorly controlled or uncontrolled hypertension (systolic blood pressure \u2265160 mm Hg\n             and/or diastolic blood pressure \u226595 mm Hg).\n\n          -  Recent history (within past 6 months) of excessive alcohol use, defined as >14 drinks\n             per week (One drink = 12 oz. beer, 4 oz. wine, 1.5 oz. hard liquor).\n\n          -  Exposure to any investigational agent within 4 weeks prior to Visit 1.\n\n          -  Has a condition the Investigator believes would interfere with the evaluation of the\n             subject, or may put the subject at undue risk during the course of the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02069106", 
            "org_study_id": "1001-PR-003-09092013"
        }, 
        "intervention": [
            {
                "arm_group_label": "Pro-Omega LDL", 
                "intervention_name": "Pro-Omega LDL", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "low density lipoprotein cholesterol", 
            "triglycerides", 
            "mixed hyperlipoproteinemia", 
            "Dehydroascorbic Acid", 
            "Eicosapentaenoic Acid", 
            "Fish oil"
        ], 
        "lastchanged_date": "May 15, 2014", 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "An 8-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Daily Pro-Omega LDL for Low-Density Lipoprotein Cholesterol and Triglyceride Reduction in Subjects With Mixed Hyperlipoproteinemia", 
        "overall_official": {
            "affiliation": "Chestnut Hill Temple Cardiology", 
            "last_name": "David Becker, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Low-density lipoprotein cholesterol (LDL-C)", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Triglycerides (TG)", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02069106"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Total cholesterol", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "High-density lipoprotein cholesterol (HDL-C)", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "non-HDL-C", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "LDL-C/HDL-C ratio", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "C-reactive protein", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "4 and 8 weeks"
            }, 
            {
                "description": "Offset effect of Pro-Omega LDL two weeks after withdrawal of placebo and Pro-Omega LDL on serum markers", 
                "measure": "Offset effect", 
                "safety_issue": "No", 
                "time_frame": "2 weeks after withdrawal"
            }
        ], 
        "source": "Nutrasource Diagnostics Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "Nordic Naturals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Nutrasource Diagnostics Inc.", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}